Will Tennessee’s PBM Bill Face the Same Fate as Arkansas’ Law?
Tennessee lawmakers recently passed a bill banning PBMs from owning pharmacies in the state, though like a similar Arkansas law, it is expected to face legal challenges if enacted.
Tennessee lawmakers recently passed a bill banning PBMs from owning pharmacies in the state, though like a similar Arkansas law, it is expected to face legal challenges if enacted.
Experts say the bipartisan Break Up Big Medicine Act — aimed at breaking up vertically integrated healthcare companies — faces slim chances of passing despite recent PBM reforms.
The Consolidated Appropriations Act of 2026 and the Department of Labor’s proposed rule implement major PBM reforms for employers, but don’t include everything they want, including a ban on spread pricing.
A judge has approved Blue Cross Blue Shield's $2.8 billion settlement with providers. However, some providers are opting out, arguing that it doesn't go far enough.
The Supreme Court upheld the constitutionality of an Affordable Care Act provision requiring insurance coverage of certain preventive services without cost-sharing. Many healthcare leaders applauded the decision, though some concerns remain.
Arkansas became the first state to pass a law banning pharmacy benefit managers from owning pharmacies, aiming to curb their market power and reduce drug costs. But major PBMs like CVS and Express Scripts are suing, claiming the law is unconstitutional.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
The Supreme Court will soon hear oral arguments for a case that threatens coverage of preventive services without cost-sharing. Experts say this could make it significantly harder for patients to access care and lead to higher costs down the road.
CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see.
After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of anticompetitive rebating practices related to insulin, the defendants reversed roles and became plaintiffs. In November, they countersued the agency, arguing that its lawsuit is unconstitutional.
The Federal Trade Commission has sued CVS Caremark, Express Scripts and Optum Rx, alleging that they engage in "anticompetitive and unfair rebating practices” as it relates to insulin. One legal expert believes the FTC might win this legal battle.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
A federal judge recently blocked the FTC's ban on noncompetes. The decision has important implications for healthcare.